Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes

Li, JW; Neal, B; Perkoyic, V; de Zeeuw, D; Neuen, BL; Arnott, C; Simpson, R; Oh, R; Mahaffey, KW; Heerspink, HJL

Heerspink, HJL (corresponding author), Univ Groningen, Univ Med Ctr, Dept Clin Pharm & Pharmacol, Groningen, Netherlands.

KIDNEY INTERNATIONAL, 2020; 98 (3): 769

Abstract

Canagliflozin reduced kidney disease progression in participants with type 2 diabetes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Pr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索